Previous close | 6.02 |
Open | 6.07 |
Bid | 5.80 x 1200 |
Ask | 5.90 x 3200 |
Day's range | 5.77 - 6.16 |
52-week range | 5.68 - 83.54 |
Volume | |
Avg. volume | 6,824,111 |
Market cap | 498.081M |
Beta (5Y monthly) | 1.78 |
PE ratio (TTM) | N/A |
EPS (TTM) | -8.52 |
Earnings date | 08 May 2023 - 12 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 50.80 |
Novavax (NASDAQ: NVAX) has had more than its share of ups and downs over the past few years -- and investors have been along for the ride. The stock soared 2,700% in 2020 as the company brought its coronavirus vaccine candidate through late-stage clinical trials. The biotech company's vaccine reached commercialization later than rivals.
Novavax (NVAX) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day.
On that note, here are a couple of severely beaten-down growth stocks that are popular among investors, but only one of them has a credible path to stay in business. With ambitions to become the world's biggest seller of legal cannabis products, Tilray Brands (NASDAQ: TLRY) is also a growth stock that's remarkably inexpensive. Despite reporting $144 million in revenue for its fiscal second quarter and free cash flow (FCF) of $25.4 million, its shares are down 42.7% in the last three years because of persistent unprofitability and wild oversupply compared to demand across several continents.